

Claim 3. A peptide is elected. The species in the claim have common denominator, a moiety that binds, inhibits, suppresses, neutralizes, or decreases activity of a biologically active agent.

#### Type of Inhibitor

Claim 4. An antibody inhibitor is elected. The species in the claim have common denominator, a biological inhibitor:

#### Active Agent

Claim 5. An antibody is elected. The species in the claim have common denominator, an agent having a biological activity.

#### Second Moiety

Claim 8. A polypeptide is elected. The species in the claim have common denominator, moiety specifically cleavable by a reagent.

Claim 9. A peptide which comprises a sequence cleavable by a protease is elected. The species in the claim have common denominator, a sequence cleavable by a protease.

Claim 10. A sequence HSSKLQ is elected. The species in the claim have common denominator, a peptide.

#### Reagent

Claim 11. A protease is elected. The species in the claim have common denominator, an enzyme.

Claim 12. A human prostate-associated protease is elected. The species in the claim have common denominator, a protease.

#### Disorder/Condition

Claim 22. A prostate cancer is elected. The disorders in the claim have common denominator, uncontrolled cell growth.


#### Conclusion

It is believed that all of the stated requirements have been met. Applicant respectfully requests that the Examiner gives due consideration to the allowability of pending Claims, which are believed to recite subject matter that is patentable. An early action allowing the pending Claims is cordially solicited.

#### AUTHORIZATION

If further extension of time is necessary to prevent abandonment of this application, then such extension of time are hereby petitioned under 37 CFR 1.136(a).

Respectfully submitted,

  
\_\_\_\_\_  
Vit Lauermann, PhD, Inventor

7904 Springway Rd.  
Baltimore, MD 21204  
Phone 410 828 0944  
FAX 410 821 7850